Adjusted probabilities of survival according to cytogenetic response and treatment (from the left truncated Cox regression model).

Patients on imatinib who achieved at least a minor cytogenetic response during the first 6 months of treatment obtained benefit when compared with patients receiving conventional treatment, whereas imatinib-treated patients who failed to respond had a poorer survival than controls. Adjusted probabilities of survival at 8 years from diagnosis were 78.4% (CI 51.3–92.6) (RR: 0.13, CI: 0.046–0.39) for imatinib responders, 22.6% (CI: 17.8–29.4) for control patients and 6.2% (CI: 2.1–16.8) (RR: 1.69, CI: 1.086–2.64) for imatinib nonresponders (see text). Other variables found to be significant in the multivariate model were age ≥ 60 years (RR: 1.58, CI: 1.16–2.14), primary hematologic resistance to interferon-α (RR: 2.62, CI: 1.69–4.07), primary cytogenetic resistance to interferon-α (RR: 0.3,CI: 0.10–0.87) and Sokal high-risk group (RR: 2.0, CI: 1.22–3.28).